Precision Medicine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Advances in Diagnosis, Risk Stratification, and Personalized Management
International Science Journal · 31.07.2026 · 4 (2)
DOI: 10.64784/267 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Science Journal, online erschienen am 31.07.2026. Verfasst von Cristóbal Washington Franco Lucas und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as one of the most prevalent chronic liver diseases worldwide and represents a growing challenge for healthcare systems due to its close relationship with obesity, insulin resistance, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome. This review aimed to integrate current scientific evidence regarding the epidemiology, pathophysiology, clinical progression, diagnosis, treatment, and emerging role of precision medicine in MASLD. International scientific literature was reviewed through recognized biomedical databases, incorporating original studies, systematic reviews, meta-analyses, clinical practice guidelines, and international consensus statements relevant to the disease. The evidence demonstrates a substantial global burden of MASLD, with particularly high prevalence estimates reported in Latin America and other regions experiencing rapid growth in cardiometabolic disorders. Disease progression is heterogeneous, ranging from hepatic steatosis to metabolic dysfunction-associated steatohepatitis, advanced fibrosis, cirrhosis, and hepatocellular carcinoma, with fibrosis representing one of the most important predictors of adverse clinical outcomes. Advances in non-invasive biomarkers, serum-based fibrosis scores, transient elastography, and magnetic resonance-based techniques have improved risk stratification and reduced dependence on liver biopsy. Lifestyle modification remains fundamental to treatment, while emerging pharmacological therapies provide additional opportunities for patients with specific metabolic and hepatic profiles. The integration of clinical characteristics, metabolic phenotype, fibrosis stage, imaging findings, and biological markers supports the transition toward precision medicine. MASLD should therefore be approached as a multisystem metabolic disease requiring early identification, multidisciplinary management, comprehensive cardiometabolic control, and individualized therapeutic strategies to reduce progression and long-term complications.
Zitieren
APA
Lucas, C. W. F., Zambrano, G. A., Acevedo, L. M. M., Villagran, G. A., González, A. M. U., Ochoa, A. D. A., Fuentes, S. G., & Ortega, A. S. F. (2026). Precision Medicine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Advances in Diagnosis, Risk Stratification, and Personalized Management. International Science Journal, 4(2). https://doi.org/10.64784/267
Vancouver
Lucas CWF, Zambrano GA, Acevedo LMM, Villagran GA, González AMU, Ochoa ADA, et al. Precision Medicine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Advances in Diagnosis, Risk Stratification, and Personalized Management. International Science Journal. 2026;4(2). doi:10.64784/267
BibTeX
@article{Lucas2026,
author = {Lucas, Cristóbal Washington Franco and Zambrano, Giancarlo Amory and Acevedo, Luis Miguel Murgas and Villagran, Gerardo Amaya and González, Andrés Mauricio Umaña and Ochoa, Ashley Denisse Ayala and Fuentes, Sandra García and Ortega, Andrés Sebastían Freire},
title = {Precision Medicine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Advances in Diagnosis, Risk Stratification, and Personalized Management},
journal = {International Science Journal},
year = {2026},
volume = {4},
number = {2},
doi = {10.64784/267}
}
EUVIMED